Which cancers can cause bursitis in various joints?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 12, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Cancers That Can Cause Bursitis in Various Joints

While bursitis is rarely a direct manifestation of cancer, certain malignancies can mimic or be associated with bursitis-like presentations, most notably soft tissue sarcomas (particularly synovial sarcoma), basal cell carcinoma, and metastatic disease to periarticular regions.

Primary Malignancies That Can Mimic Bursitis

Soft Tissue Sarcomas

Synovial sarcoma is the most clinically relevant cancer that can masquerade as bursitis, particularly in young patients. A recent case report documented a 17-year-old with a 4-year history of anterior knee pain initially diagnosed as infrapatellar bursitis on noncontrast MRI, which was ultimately synovial sarcoma 1. This highlights a critical diagnostic pitfall: soft tissue sarcomas can present with imaging characteristics that mimic benign inflammatory conditions.

Soft tissue sarcomas arise from mesenchymal tissues including fat, muscle, nerves, blood vessels, and connective tissues 2. They most commonly occur in:

  • Extremities (43%)
  • Retroperitoneum (15%)
  • Trunk (10%)
  • Head and neck (9%)

Key clinical red flags that distinguish sarcoma from true bursitis:

  • Persistent non-mechanical pain, especially night pain
  • Progressive swelling over weeks to months
  • Young age (particularly for synovial sarcoma)
  • Lack of response to standard bursitis treatments
  • Mass effect beyond what would be expected for simple bursitis

Skin Cancers

Basal cell carcinoma can present as a mass lesion mimicking both dermoid cyst and bursitis. A documented case involved a 67-year-old man with 2 years of knee pain and tumor initially diagnosed as dermoid cyst and bursitis, ultimately confirmed as BCC 3. This underscores that any periarticular mass with overlying skin changes warrants dermatologic evaluation.

Squamous Cell Carcinoma

Chronic olecranon bursitis represents a specific risk factor for malignant transformation to squamous cell carcinoma 4. A case documented a 70-year-old with 12-year history of chronic, non-healing olecranon bursitis that progressed to SCC, ultimately requiring amputation. Chronic inflammatory states, particularly with non-healing wounds, can undergo malignant transformation.

Metastatic Disease Mimicking Bursitis

Ischiogluteal Bursitis and Metastatic Disease

Metastatic disease can present as or coexist with bursitis. A case report documented ischiogluteal bursitis mimicking soft tissue metastasis from renal cell carcinoma 5. Additionally, eight cancer patients with metastatic disease developed severe back and leg pain from ischiogluteal bursitis, which was effectively treated with local corticosteroid injection 6.

Metastatic disease most commonly affects:

  • Spine, pelvis, and ribs (most common skeletal sites)
  • Humerus (second most affected long bone after femur) 7
  • 20% of metastatic bone disease occurs in upper extremity

Primary Cancers That Metastasize to Periarticular Regions

The most common primary cancers that metastasize to bone and periarticular soft tissues include:

  • Breast carcinoma
  • Lung carcinoma
  • Prostate carcinoma
  • Renal cell carcinoma
  • Multiple myeloma (primary bone marrow malignancy)

Bone Sarcomas Presenting Near Joints

Osteosarcoma

Most commonly arises in the metaphysis of long bones around the knee 8. Presents with:

  • Non-mechanical or night pain
  • Swelling only when tumor breaches cortex and distends periosteum
  • Peak incidence in adolescents (15-19 years)

Ewing Sarcoma

Affects extremity bones in 50% of cases, with pelvis, ribs, and vertebrae also commonly involved 9, 8. Unlike other bone sarcomas, may present with constitutional symptoms (fever, weight loss, fatigue) that could be confused with infectious bursitis.

Chondrosarcoma

Arises in diametaphyseal regions of long bones and flat bones (pelvis, rib, scapula) 8. Peak age 30-60 years. High-grade variants frequently involve axial skeleton and long bones near joints.

Diagnostic Algorithm for Suspected Malignancy

When bursitis fails to respond to standard treatment or presents atypically, pursue the following:

  1. Obtain plain radiographs in two planes first 10, 8, 11

    • Look for: bone destruction, periosteal reaction, soft tissue mass, calcifications
  2. If radiographs are negative/equivocal but clinical suspicion remains high:

    • MRI of entire compartment with adjacent joints is the gold standard for soft tissue evaluation 10, 11
    • Contrast-enhanced MRI helps differentiate fluid from synovitis/tumor
    • CT for better visualization of calcifications and cortical destruction
  3. Red flags mandating immediate advanced imaging and referral:

    • Persistent pain >4-6 weeks despite appropriate treatment
    • Night pain or non-mechanical pain
    • Progressive swelling
    • Age <25 years with atypical presentation
    • Palpable mass beyond expected bursal dimensions
    • Constitutional symptoms (fever, weight loss)
    • History of prior malignancy
  4. Biopsy considerations:

    • All suspected bone or soft tissue sarcomas must be referred to specialized sarcoma center BEFORE biopsy 9, 11
    • Core needle biopsy under imaging guidance is often appropriate
    • Biopsy tract must be planned for subsequent definitive resection
    • Send tissue for microbiological culture if infection is differential

Critical Clinical Pitfalls to Avoid

  • Never assume chronic bursitis is benign without tissue diagnosis, especially with non-healing wounds or atypical features
  • Do not delay imaging in young patients with persistent joint pain—synovial sarcoma can mimic bursitis for years 1
  • Recent trauma does not exclude malignancy and should not prevent appropriate diagnostic workup 11
  • Hemorrhagic bursitis can occur with myeloproliferative disorders 12, warranting hematologic evaluation if recurrent
  • In cancer patients with new "bursitis," maintain high suspicion for metastatic disease even if imaging initially suggests benign bursitis 5, 6

Management Implications

For confirmed malignancy mimicking bursitis:

  • Soft tissue sarcomas require wide excision with multidisciplinary team management 2
  • Metastatic bone disease may require surgical stabilization if impending fracture (particularly humerus) 7
  • Chronic inflammatory bursitis with malignant transformation may require radical excision or amputation 4

The key principle: persistent or atypical "bursitis" warrants aggressive diagnostic evaluation to exclude malignancy, as delayed diagnosis significantly impacts morbidity and mortality.

References

Guideline

soft tissue sarcoma, version 2.2022, nccn clinical practice guidelines in oncology.

Journal of the National Comprehensive Cancer Network : JNCCN, 2022

Guideline

the musculoskeletal tumor society clinical practice guideline on the management of metastatic humeral disease.

The Journal of the American Academy of Orthopaedic Surgeons, 2024

Guideline

acr appropriateness criteria<sup>®</sup> chronic hip pain.

Journal of the American College of Radiology, 2017

Research

Hemorrhagic subcutaneous bursitis.

The Journal of rheumatology, 1991

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.